Search Results
Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Acalabrutinib
Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with
- Mantle cell lymphoma (MCL) who have received at least one prior therapy
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Topotecan
Topotecan is an FDA-approved cancer drug that is used to treat people who have certain types of cancer including acute myeloid leukemia and acute lymphoblastic leukemia. This drug may cause a temporary loss of hair in some people. After treatment with topotecan has ended, normal hair growth should return.
#ASH15 Day 3: Big Advances in Treating Chronic Lymphocytic Leukemia
John Byrd, M.D., of the Ohio State University Comprehensive Cancer Center, is one of the world’s renowned scientists in the field of blood cancer. LLS has been supporting his work for the better part of two decades. While Byrd has, of late, turned his attention to the problem of finding better therapies for patients with acute myeloid leukemia (AML), it is in chronic lymphocytic leukemia (CLL) that he has made his mark.
Is a Clinical Trial Right For You?
Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.
Progress on AML but More Work to Do
A Q&A with Amy Burd, PhD, LLS Vice President of Research Strategy
Today is AML World Awareness Day, a day to acknowledge the struggle to tackle one of the most challenging blood cancers, while shining a light on advances in the prevention, management and treatment of acute myeloid leukemia (AML).
Against All Odds, Eevie Turns 1!
A first birthday is always a big occasion, but for Eevie, it's taken on a whole new meaning. She was born with a rare leukemia that gives her a 17 percent chance of surviving to age 2. Even her parents weren't sure she would make it this far. "We didn't think she would still be here. The odds were never in her favor," said her mom, Brynne. Eevie was born with congenital acute lymphoblastic leukemia (ALL), an extremely rare condition affecting 1 in 5 million newborns.
Young Advocate, Big Goals: Charlotte’s Story
Imagine going to the doctor for a cold only to learn you actually have leukemia. That’s how Charlotte's experience with blood cancer began in 2018.
“The doctor diagnosed it as strep throat,” Charlotte remembers. When the antibiotics didn’t work, she “went to another doctor who diagnosed it as something else.”
Hydroxyurea
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.